Publication: Cost-utility analysis of drug treatments in patients with polypoidal choroidal vasculopathy in Thailand
Issued Date
2021-01-01
Resource Type
ISSN
11786981
Other identifier(s)
2-s2.0-85118967746
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
ClinicoEconomics and Outcomes Research. Vol.13, (2021), 917-926
Suggested Citation
Sermsiri Sangroongruangsri, Usa Chaikledkaew, Prut Hanusaha, Tanapat Ratanapakorn, Paisan Ruamviboonsuk Cost-utility analysis of drug treatments in patients with polypoidal choroidal vasculopathy in Thailand. ClinicoEconomics and Outcomes Research. Vol.13, (2021), 917-926. doi:10.2147/CEOR.S340570 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/76880
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cost-utility analysis of drug treatments in patients with polypoidal choroidal vasculopathy in Thailand
Abstract
Purpose: The aim of this study was to estimate the cost-utility and budget impact of pharmacological treatments for the eye with polypoidal choroidal vasculopathy (PCV) in Thailand. Methods: A Markov model-based cost-utility analysis (CUA) and budget impact analysis were conducted. The lifetime cost and outcomes of PCV treatments were estimated. We discounted costs and outcomes at 3% per annum. Parameters were estimated using data from published literatures, local cost and utility data, and epidemiology data among Thai patients. Univariate and probabilistic sensitivity analyses were performed to account for parameter uncertainty. Results: Intravitreal bevacizumab (IVB) resulted in the lowest lifetime cost, followed by IVB plus verteporfin photodynamic therapy (IVB+vPDT) and intravitreal aflibercept (IVA). The combination of IVB or intravitreal ranibizumab (IVR) and verteporfin photodynamic therapy (IVB+vPDT or IVR+vPDT) yielded the highest quality-adjusted life-years (QALY). When compared with IVB from a societal perspective, the incremental cost-effectiveness ratio for patients with PCV receiving IVB+vPDT, IVR+vPDT, IVA were 10,304; 54,135; and 82,738 the United States dollar (USD) per QALY gained, respectively. At the Thai societal willingness to pay threshold of 4884 USD, IVB had the highest probability of being cost-effective (99%) followed by IVB+vPDT (1%). IVB+vPDT could be a cost-effective strategy and required a budget of 12.61 million USD over five fiscal years when the price of verteporfin reduced by approximately 45%. Conclusion: None of the drug treatments for PCV was cost-effective in the Thai context. The decreased price of verteporfin is required to support the inclusion of IVB+vPDT in the Thai National List of Essential Medicines for the treatment of PCV.